Steven de Kosky

This company has been started by two researchers who have worked in Alzheimer's disease (AD) for many years. The plan is to use combination therapy In subjects with early AD. One of the medications is an FDA-approved drug. The other is an antibody directed toward amyloid, one of the abnormal proteins that accumulate in AD. I will be advising the company on clinical study design and chairing their scientific advisory board. At some point they may ask members of the scientific advisory board to either help them with discussions with the FDA concerning a trial, or accompany them to a meeting at the FDA. The latter would be on vacation time. The attached letter/agreement represents what Recuerdo would like to do, and serves as their contract with me. However, so far they have not succeeded in getting Qualified Financing, so nothing is happening. While there are proposed meetings scheduled and consulting monies proposed, none of these things has come to pass, and it is not clear when they will be ready to move forward. When they do I will alter the report. I have listed an estimated amount of remuneration; they feel currently that they owe approximately $6,000 to me at this point. All of the work I have done has been on weekends or in the evenings; there have been no meetings or conference calls. They had scheduled a meeting of the 3 members of the SAB in early June but cancelled it. Therefore I am uncertain about how to further characterize the time commitment and expected remuneration.